Company Information

  

Address: ONE KENDALL SQUARE
BUILDING 200, STE. 2203 
City: CAMBRIDGE 
State: MA 
Zip Code: 02139 
Telephone: (857) 999-0075 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors. Our first product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema ("HAE") and diabetic macular edema ("DME"). We apply our insights into the chemistry of proteases and, with our current programs, the biology of the plasma kallikrein system, to develop molecules with properties such as selectivity, potency and bioavailability that we believe will make them successful treatments for disease. There is good evidence that inhibition of plasma kallikrein is able to treat HAE. Currently marketed therapies are all administered by injection and we anticipate considerable potential for orally delivered, small molecule treatments.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
04/2017-4.47NAN/E
09/2016103.88NA0.06

Key Financial Ratios and Statistics

FYE: 04/30

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.21Total Liab/Total Assets0.09
Net Inc/Total Assets-0.54Total Liab/Inv Cap0.10
Net Inc/Inv Cap-0.59Total Liab/Comm Equity0.03
Pretax Inc/Net Sales-12.37Interest Coverage RatioNA
Net Inc/Net Sales-12.37Curr Debt/EquityNA
Cash Flow/Net Sales-15.77LTD/EquityNA
SG&A/NetSales7.43Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover0.63Quick Ratio11.35
Inventory TurnoverNACurrent Ratio11.35
Inventory Day SalesNANet Rec/Curr Assets0.07
Net Sales/Work Cap0.05Inv/Curr AssetsNA
Net Sales/PP&E15.51  

Income Statement (Millions)

  7/31/2017 4/30/2017 6/30/2016
Total Revenues(Net Sales) 0.10 0.11 0.01
Cost of Goods Sold NA NA NA
Selling & Admin Exps 2.07 2.20 4.15
Operating Income -5.45 -5.09 -13.49
Interest Exp NA NA 0.49
Pretax Income -4.93 -4.20 -13.96
Other Income 0.53 0.88 0.03
Net Income Bef Extraordinary ... NA NA NA
Net Income -4.93 -4.20 -13.96

Balance Sheet (Millions)

Assets 7/31/2017 4/30/2017 6/30/2016
Cash & Short Term Investments 26.46 30.95 36.82
Receivables - Total 2.90 2.55 NA
Inventories - Total NA NA NA
Total Current Assets 30.19 34.25 37.96
Net Property, Plant & Equipment 0.59 0.10 0.00
Total Assets 30.78 34.35 38.01
Liabilities      
Accounts Payable 3.64 3.02 1.90
Debt in Current Liabilities 0.20 NA 0.00
Total Current Liabilities 3.84 3.02 1.93
Long-Term Debt 0.21 NA 0.00
Total Liabilities 4.05 3.02 1.97
Stockholder's Equity      
Minority Interest NA NA NA
Preferred Stock NA NA 0.00
Common Stock 0.01 0.01 0.03
Retained Earnings -60.78 -55.86 -86.58
Treasury Stock NA NA NA
Total Stockholders' Equity 26.73 31.33 36.04
Total Liabilities and Stockholders' Equity 30.78 34.35 38.01

Cash Flow Summary (Millions)

Categories 7/31/2017 4/30/2017 6/30/2016
Net Cash Provided by Operating Activities -4.45 -2.64 -12.34
Net Cash Provided by Investing Activities -0.11 -0.01 -0.06
Net Cash Provided by Financing Activities 0.00 0.00 -4.50

Annual Summary Data (Millions)

Year Sales Net Income EPS
04/20140.03-13.36--
04/20150.03-24.85--
04/20160.01-6.61--
04/20160.01-6.61--
04/20171.50-18.60-4.47
Growth Rates168.36----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17197,39276.11




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.